The UK-based biotechnology organization developing targeted therapies for oncology and virology.

We are delighted to end up being partnered with Astex in support of the clinical development of AT7519. .. Astex and MMRC commence Stage II clinical trial of AT7519 CDK inhibitor in multiple myeloma Astex Therapeutics, the UK-based biotechnology organization developing targeted therapies for oncology and virology, and the Multiple Myeloma Analysis Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to take care of sufferers with refractory or relapsed multiple myeloma, an incurable blood cancer. This scientific trial will be executed through MMRC Member Organization sites and others in the USA.Chan happens to be overseeing the WHO’s response to the risk of bird flu, and the possibility of a flu pandemic. She has had extensive experience and spent nine years as director of Hong Kong’s department of health, where she won praise for helping fight the world’s initial outbreak of bird flu in 1997. It was Dr. Chan’s decision to cull about 1.5m poultry in the face of stiff opposition which was crucial in assisting to stem the spread of the virus. She also has experience in working with another deadly respiratory disease, SARS, which spread from Asia into other areas of the world in 2002-2003. Nevertheless, she was criticised at home for allegedly failing woefully to get speedy info from mainland China where in fact the disease started.